Prelude Capital Management’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Prelude Capital Management’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-923	Closed	-$13K	–	2225
2019 Q2	$13K	Sell	923 -30,263	-97%	-$463K	﹤0.01%	1356
2019 Q1	$537K	Buy	31,186 +435	+1%	+$6.88K	0.03%	481
2018 Q4	$393K	Buy	30,751 +7,859	+34%	+$119K	0.03%	531
2018 Q3	$372K	Buy	+22,892	New	+$327K	0.02%	610
2017 Q4	–	Sell	-17,482	Closed	-$294K	–	1858
2017 Q3	$294K	Sell	17,482 -6,478	-27%	-$105K	0.03%	524
2017 Q2	$403K	Buy	23,960 +8,323	+53%	+$124K	0.04%	378
2017 Q1	$242K	Buy	15,637 +3,100	+25%	+$44.3K	0.02%	501
2016 Q4	$187K	Buy	+12,537	New	+$176K	0.02%	610

Other funds holding OXFD

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Prelude Capital Management's OXFD Position: Q3 2019 in Review

Prelude Capital Management sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q3 2019, closing a stake of 923 shares — an estimated $13K sold.

Prelude Capital Management first reported a position in OXFD in Q4 2016 and held it in 8 quarters. The position peaked at $537K in Q1 2019. 73 funds tracked by Wall St. Rank hold OXFD as of Q3 2019.

Prelude Capital Management reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q3 2019 after selling out during the quarter.
Prelude Capital Management sold 923 Oxford Immunotec Global PLC Ordinary Shares shares in Q3 2019, an estimated $13K.
Prelude Capital Management first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2016 and held it in 8 quarters.
Prelude Capital Management's Oxford Immunotec Global PLC Ordinary Shares position peaked at $537K in Q1 2019.
73 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q3 2019.

Based on Prelude Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.